US respiratory portfolio to drive medium term sales growth for Cipla

Near-term gains from the increased demand for Covid-related drugs, medium-term traction from the chronics portfolio, and fresh launches in the US are expected to sustain the revenue and earnings growth trajectory for Cipla. These triggers, coupled with a preference for pharma and defensive stocks amid the second wave of Covid in India, saw Cipla gain nearly 25 per cent over the past month.

The immediate trigger is the rising demand for anti-viral and other formulations used for the treatment of coronavirus infection. The company, which accounts for about half the Remdesivir …